文献速递肺栓塞与肺血管病

沙特阿拉伯肺动脉高压:SAUDIPH登记研究首报聚焦动脉性肺动脉高压

Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension.
PubMed 文献 · Respirology · 2020-06-15

SAUDIPH登记研究纳入2004至2018年一家三级中心管理的222例第1组和第4组肺动脉高压患者,第1组最常见(57.7%),诊断平均年龄32岁。末次随访时83.7%使用特异性治疗,30%患者功能分级从III/IV级改善至I/II级,NT-proBNP整体改善29.2%。1年、3年和5年累积生存概率分别为95.6%、89.2%和74.6%。

要点

  • 第1组肺动脉高压占比57.7%,诊断平均年龄32岁,mPAP为55.0 mmHg。
  • 末次随访83.7%接受特异性治疗,30%患者功能分级改善,NT-proBNP改善29.2%。
  • 1年、3年、5年累积生存率分别为95.6%、89.2%、74.6%。

核心结论

  • 第1组肺动脉高压是最常见病因,患者诊断年龄较其他队列年轻。
  • 多数患者功能分级和NT-proBNP改善,1年生存率优于既往研究,可能反映联合治疗更广泛使用和CHD-PAH高患病率。

研究设计与样本

  • SAUDIPH登记研究,纳入2004至2018年一家三级专科中心临床管理的第1组和第4组肺动脉高压患者,共222例。

主要发现

  • 第1组肺动脉高压占57.7%,诊断平均年龄32岁,mPAP为55.0 mmHg。
  • 第1组mPAP为59.0 mmHg,高于总体(P < 0.001)。
  • 末次随访时83.7%患者使用特异性治疗,30%患者功能分级从III/IV级改善至I/II级。
  • NT-proBNP在总体人群中改善29.2%。
  • 1年、3年、5年累积生存概率分别为95.6%(95% CI: 91.5-99.9%)、89.2%(95% CI: 82.1-96.9%)、74.6%(95% CI: 59.4-93.7%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: This study presents the first results of 'SAUDIPH' registry, aiming to assess patient characteristics, treatment approach and clinical and survival outcomes in patients with PAH. METHODS: The registry enrolled patients with Group 1 and Group 4 PH under clinical management in a specialized tertiary care centre from 2004 to 2018. Changes from baseline to last follow-up visit were assessed. RESULTS: A total of 222 patients were enrolled, and Group 1 PH was the most frequent aetiology (57.7%). Mean age at diagnosis was 32 years. mPAP was 55.0 mm Hg and was higher for Group 1 PH (59.0 mm Hg, P < 0.001). At the last visit, most patients were on specific therapy (83.7%) and 30% shifted from FC III/IV to FC I/II. NT-proBNP improved by 29.2% in the overall population. The 1-, 3- and 5-year cumulative probabilities of survival were 95.6% (95% CI: 91.5-99.9%), 89.2% (95% CI: 82.1-96.9%) and 74.6% (95% CI: 59.4-93.7%), respectively. CHD-PAH demonstrated the best survival among Group 1 PAH with 1-, 3- and 5-year cumulative probability of 100%, 100%, and 75.0% (95% CI: 42.6-100), respectively. CONCLUSION: PAH was the most frequent aetiology and patients were younger at diagnosis compared to other cohorts. Most patients showed improvement in FC and NT-proBNP. The estimated 1-year survival was better than previous studies, possibly reflecting wider use of combination therapy and the high prevalence of CHD-PAH.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Aldalaan AM, Saleemi SA, Weheba I, et al. Pulmonary hypertension in Saudi Arabia: First data from the SAUDIPH registry with a focus on pulmonary arterial hypertension. Respirology. 2020. PMID: 32542977. doi:10.1111/resp.13879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。